EU Mobile App For Reporting ADRs To Be Tested In Burkina Faso And Zambia
Executive Summary
An app for reporting adverse drug reactions developed by Europe’s Innovative Medicines Initiative is being tested in two African countries, where the mobile infrastructure is said to be more advanced than in EU. The app is expected to help in the collection of ADR data from malaria programs and from general medicines use.
You may also be interested in...
EU ADR app to underpin region's regulatory approach to social media
Europe is set to modernize how it conducts some aspects of pharmacovigilance with the launch of a web app in March this year for patients to report adverse drug reactions (ADRs) and a drive to monitor web chatter on the issue. Mick Foy, Group Manager Vigilance Intelligence at the UK’s Medicines and Healthcare products Regulatory Agency, has warned that without progress on the social-media front, manufacturers might shy away from the area to avoid a legal and ethical minefield.
Global Medtech Guidance Tracker: February 2021
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.
First Oral Treatment For Spinal Muscular Atrophy Gets EMA Nod
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: